395 related articles for article (PubMed ID: 30291183)
1. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum.
Illán-Gala I; Alcolea D; Montal V; Dols-Icardo O; Muñoz L; de Luna N; Turón-Sans J; Cortés-Vicente E; Sánchez-Saudinós MB; Subirana A; Sala I; Blesa R; Clarimón J; Fortea J; Rojas-García R; Lleó A
Neurology; 2018 Oct; 91(17):e1619-e1628. PubMed ID: 30291183
[TBL] [Abstract][Full Text] [Related]
2. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
Alcolea D; Vilaplana E; Suárez-Calvet M; Illán-Gala I; Blesa R; Clarimón J; Lladó A; Sánchez-Valle R; Molinuevo JL; García-Ribas G; Compta Y; Martí MJ; Piñol-Ripoll G; Amer-Ferrer G; Noguera A; García-Martín A; Fortea J; Lleó A
Neurology; 2017 Jul; 89(2):178-188. PubMed ID: 28592456
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
[TBL] [Abstract][Full Text] [Related]
4. Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD.
Alcolea D; Irwin DJ; Illán-Gala I; Muñoz L; Clarimón J; McMillan CT; Fortea J; Blesa R; Lee EB; Trojanowski JQ; Grossman M; Lleó A
J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):180-186. PubMed ID: 30297518
[TBL] [Abstract][Full Text] [Related]
5. CSF neurofilament light concentration is increased in presymptomatic
Rostgaard N; Roos P; Portelius E; Blennow K; Zetterberg H; Simonsen AH; Nielsen JE
Neurology; 2018 Jan; 90(2):e157-e163. PubMed ID: 29237796
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.
Abu-Rumeileh S; Vacchiano V; Zenesini C; Polischi B; de Pasqua S; Fileccia E; Mammana A; Di Stasi V; Capellari S; Salvi F; Liguori R; Parchi P;
J Neurol; 2020 Jun; 267(6):1699-1708. PubMed ID: 32100123
[TBL] [Abstract][Full Text] [Related]
7. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase.
Oeckl P; Weydt P; Steinacker P; Anderl-Straub S; Nordin F; Volk AE; Diehl-Schmid J; Andersen PM; Kornhuber J; Danek A; Fassbender K; Fliessbach K; ; Jahn H; Lauer M; Müller K; Knehr A; Prudlo J; Schneider A; Thal DR; Yilmazer-Hanke D; Weishaupt JH; Ludolph AC; Otto M
J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):4-10. PubMed ID: 30224549
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease.
Gaiani A; Martinelli I; Bello L; Querin G; Puthenparampil M; Ruggero S; Toffanin E; Cagnin A; Briani C; Pegoraro E; Sorarù G
JAMA Neurol; 2017 May; 74(5):525-532. PubMed ID: 28264096
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum.
Meeter LHH; Vijverberg EG; Del Campo M; Rozemuller AJM; Donker Kaat L; de Jong FJ; van der Flier WM; Teunissen CE; van Swieten JC; Pijnenburg YAL
Neurology; 2018 Apr; 90(14):e1231-e1239. PubMed ID: 29514947
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
[TBL] [Abstract][Full Text] [Related]
11. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
12. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
13. Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with
Barschke P; Oeckl P; Steinacker P; Al Shweiki MR; Weishaupt JH; Landwehrmeyer GB; Anderl-Straub S; Weydt P; Diehl-Schmid J; Danek A; Kornhuber J; Schroeter ML; Prudlo J; Jahn H; Fassbender K; Lauer M; van der Ende EL; van Swieten JC; Volk AE; Ludolph AC; Otto M;
J Neurol Neurosurg Psychiatry; 2020 May; 91(5):503-511. PubMed ID: 32132225
[TBL] [Abstract][Full Text] [Related]
14. Significance of CSF NfL and tau in ALS.
Schreiber S; Spotorno N; Schreiber F; Acosta-Cabronero J; Kaufmann J; Machts J; Debska-Vielhaber G; Garz C; Bittner D; Hensiek N; Dengler R; Petri S; Nestor PJ; Vielhaber S
J Neurol; 2018 Nov; 265(11):2633-2645. PubMed ID: 30187162
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival.
Skillbäck T; Mattsson N; Blennow K; Zetterberg H
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Aug; 18(5-6):397-403. PubMed ID: 28631955
[TBL] [Abstract][Full Text] [Related]
17. Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease.
Baldacci F; Toschi N; Lista S; Zetterberg H; Blennow K; Kilimann I; Teipel S; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Bonuccelli U; Hampel H
Alzheimers Dement; 2017 Sep; 13(9):993-1003. PubMed ID: 28263742
[TBL] [Abstract][Full Text] [Related]
18. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.
Tortelli R; Ruggieri M; Cortese R; D'Errico E; Capozzo R; Leo A; Mastrapasqua M; Zoccolella S; Leante R; Livrea P; Logroscino G; Simone IL
Eur J Neurol; 2012 Dec; 19(12):1561-7. PubMed ID: 22680408
[TBL] [Abstract][Full Text] [Related]
19. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.
Lu CH; Macdonald-Wallis C; Gray E; Pearce N; Petzold A; Norgren N; Giovannoni G; Fratta P; Sidle K; Fish M; Orrell R; Howard R; Talbot K; Greensmith L; Kuhle J; Turner MR; Malaspina A
Neurology; 2015 Jun; 84(22):2247-57. PubMed ID: 25934855
[TBL] [Abstract][Full Text] [Related]
20. CSF angiogenin levels in amyotrophic lateral Sclerosis-Frontotemporal dementia spectrum.
Morelli C; Tiloca C; Colombrita C; Zambon A; Soranna D; Lafronza A; Solca F; Carelli L; Poletti B; Doretti A; Verde F; Maderna L; Ticozzi N; Ratti A; Silani V
Amyotroph Lateral Scler Frontotemporal Degener; 2020 Feb; 21(1-2):63-69. PubMed ID: 31852251
[No Abstract] [Full Text] [Related]
[Next] [New Search]
